Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


John Youshia has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design and optimization of inherently cytotoxic nanostructured lipid carriers as drug vehicles with dual anti-cancer activity

    by John Youshia, Mera Medhat, Mariam George, Haidy Maged, Maureen Sherif, Salma Ashraf, Sara Ahmed, Felopateer Karam, Wafaa Ibrahim, Mariam Samir, et al.


  • Open Access

    Folic Acid-Decorated Lipidic Nanocapsules Co-Loaded with Atorvastatin and Curcumin to Enhance Glioma Targeting in Mice

    by Mahitab Bayoumi, John Youshia, O. A. El-Kawy, Sara A. Abdel Gaber, Mona G. Arafa, Maha Nasr, Omaima A. Sammour

    Background: Glioma remains an intractable and highly aggressive brain tumor, mainly due to the daunting obstacle presented by the blood–brain barrier (BBB). To overcome this challenge and enhance therapeutic efficacy, a dual-drug delivery system was engineered. This system co-encapsulated curcumin, a nutraceutical with multitargeted anticancer potential, with atorvastatin calcium, a repurposed anticancer agent, within lipidic nanocapsules (LNCs). Methods: LNCs were prepared via the phase inversion temperature method and optimized using a Box–Behnken design. The optimized LNCs were subsequently functionalized with folic acid (FA) to enable active targeting. FA-LNCs were characterized using XPS, TEM, in vitro release, and MTT cytotoxicity assays. Atorvastatin and curcumin were radiolabeled separately with iodine-131 to evaluate the in vivo pharmacokinetics in a glioma-bearing mouse model. Results: The optimized LNCs and FA-LNCs displayed a mean particle size of 97.98 ± 2.27 nm and 181.60 ± 2.83 nm, a polydispersity index of 0.32 ± 0.07 and 0.40 ± 0.02, and a zeta potential of −15.85 ± 1.35 mV and −11.90 ± 2.80, respectively. XPS and FTIR analyses verified FA conjugation. Both LNCs and FA-LNCs enhanced the in vitro cytotoxicity compared to free drugs; however, the most pronounced effect of FA functionalization was observed in vivo. Most significantly, FA-LNCs achieved markedly greater glioma accumulation than non-functionalized LNCs, with AUC values 2.0-fold higher for atorvastatin and 2.6-fold higher for curcumin. When compared to the free drug solutions, this efficiency was even more pronounced, with atorvastatin and curcumin showing enhancements of 8.2 and 12.4 times, respectively. Conclusions: FA-LNCs markedly improved glioma targeting efficiency and reduced systemic clearance, which underscores the therapeutic potential of integrating nutraceuticals with repurposed agents to achieve effective glioma therapy.


  • Open Access

    Chitosan Nanoparticles for Topical Drug Delivery in Chemotherapy-Induced Alopecia: A Comparative Study of Five Repurposed Pharmacological Agents

    by Salma A. Fereig, John Youshia, Ghada M. El-Zaafarany, Mona G. Arafa, Mona M. A. Abdel-Mottaleb

    Background/Objectives: Chemotherapy-induced alopecia is a common and distressing side effect of cancer treatment, significantly impacting patients’ psychological well-being. Nanocarriers offer a promising strategy for targeted drug delivery to hair follicles, while chitosan nanoparticles have demonstrated hair-growth-promoting properties. This study explores the potential of chitosan nanoparticles as a topical delivery system for five pharmacological agents—phenobarbital, pioglitazone, rifampicin, N-acetylcysteine, and tacrolimus—to prevent chemotherapy-induced alopecia. Methods: Drug-loaded chitosan nanoparticles were prepared using the ionic gelation technique and characterized by particle size, zeta potential, entrapment efficiency, FT-IR spectroscopy, and TEM imaging. Their efficacy was assessed in a cyclophosphamide-induced alopecia model in C57BL/6 mice through macroscopic observation, histopathological examination, and scanning electron microscopy of regrown hair. Results: The prepared particles were spherical, cationic, and between 205 and 536 nm in size. The entrapment efficiencies ranged from 8% to 63%. All five drugs mitigated follicular dystrophy, shifting the hair follicle response from dystrophic catagen to dystrophic anagen. Phenobarbital demonstrated the most significant hair regrowth and quality improvements, followed by N-acetyl cysteine and pioglitazone. Tacrolimus showed moderate efficacy, while rifampicin was the least effective. Conclusions: These findings suggest that phenobarbital-loaded chitosan nanoparticles represent a promising approach for the prevention and treatment of chemotherapy-induced alopecia, warranting further investigation for clinical applications.


  • Nanocarriers for the treatment of glioblastoma multiforme: A succinct review of conventional and repositioned drugs in the last decade

    by Mahitab Bayoumi, John Youshia, Mona G. Arafa, Maha Nasr, Omaima A. Sammour

    Glioblastoma multiforme is a very combative and threatening type of cancer. The standard course of treatment involves excising the tumor surgically, then administering chemotherapy and radiation therapy. Because of the presence of the blood–brain barrier and the unique characteristics of the tumor microenvironment, chemotherapy is extremely difficult and has a high incidence of relapse. With their capacity to precisely target and transport therapeutic medications to the tumor while overcoming the challenges provided by invasive and infiltrative gliomas, nanocarriers offer a potentially beneficial treatment option for gliomas. Drug repositioning or, in other words, finding novel therapeutic uses for medications that have received approval for previous uses has also recently emerged to provide alternative treatments for many diseases, with glioblastoma being among them. In this article, our goal is to shed light on the pathogenesis of glioma and summarize the proposed treatment approaches in the last decade, highlighting how combining repositioned drugs and nanocarriers technology can reduce drug resistance and improve therapeutic efficacy in primary glioma.


  • Open Access

    Gastroprotective Chitosan Nanoparticles Loaded with Oleuropein: An In Vivo Proof of Concept

    by Hend Abd-Allah, John Youshia, Gehad A. Abdel Jaleel, Azza Hassan, Mevidette El Madani, Maha Nasr

    Oleuropein is the main constituent of olive leaf extract, and it has shown antioxidant and gastroprotective properties against gastric ulcers. Chitosan nanoparticles are known for their mucoadhesive abilities, and consequently, they can increase the retention time of drugs in the gastrointestinal tract. Therefore, loading oleuropein onto chitosan nanoparticles is expected to enhance its biological efficiency. Oleuropein-loaded chitosan nanoparticles were prepared and characterized for particle size, surface charge, in vitro release, and anti-inflammatory activity. Their in vivo efficacy was assessed by measuring specific inflammatory and protective biomarkers, along with histopathological examination. The optimum oleuropein chitosan nanoparticles were cationic, had a size of 174.3 ± 2.4 nm and an entrapment efficiency of 92.81%, and released 70% of oleuropein within 8 h. They recorded a lower IC50 in comparison to oleuropein solutions for membrane stabilization of RBCs (22.6 vs. 25.6 µg/mL) and lipoxygenase inhibition (7.17 vs. 15.6 µg/mL). In an ethanol-induced gastric ulcer in vivo model, they decreased IL-1β, TNF-α, and TBARS levels by 2.1, 1.7, and 1.3 fold, respectively, in comparison to increments caused by exposure to ethanol. Moreover, they increased prostaglandin E2 and catalase enzyme levels by 2.4 and 3.8 fold, respectively. Immunohistochemical examination showed that oleuropein chitosan nanoparticles markedly lowered the expression of IL-6 and caspase-3 in gastric tissues in comparison to oleuropein solution. Overall, oleuropein chitosan nanoparticles showed superior gastroprotective effects to oleuropein solution since comparable effects were demonstrated at a 12-fold lower drug dose, delineating that chitosan nanoparticles indeed enhanced the potency of oleuropein as a gastroprotective agent.


  • Open Access

    Metabolomics-directed nanotechnology in viral diseases management: COVID-19 a case study

    by Marwa O. El-Derany, Diana M. F. Hanna, John Youshia, Enas Elmowafy, Mohamed A. Farag, Samar S. Azab

    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently regarded as the twenty-first century’s plague accounting for coronavirus disease 2019 (COVID-19). Besides its reported symptoms affecting the respiratory tract, it was found to alter several metabolic pathways inside the body. Nanoparticles proved to combat viral infections including COVID-19 to demonstrate great success in developing vaccines based on mRNA technology. However, various types of nanoparticles can affect the host metabolome. Considering the increasing proportion of nano-based vaccines, this review compiles and analyses how COVID-19 and nanoparticles affect lipids, amino acids, and carbohydrates metabolism. A search was conducted on PubMed, ScienceDirect, Web of Science for available information on the interrelationship between metabolomics and immunity in the context of SARS-CoV-2 infection and the effect of nanoparticles on metabolite levels. It was clear that SARS-CoV-2 disrupted several pathways to ensure a sufficient supply of its building blocks to facilitate its replication. Such information can help in developing treatment strategies against viral infections and COVID-19 based on interventions that overcome these metabolic changes. Furthermore, it showed that even drug-free nanoparticles can exert an influence on biological systems as evidenced by metabolomics. Graphical abstract


  • Nose to brain delivery of naringin-loaded chitosan nanoparticles for potential use in oxaliplatin-induced chemobrain in rats: impact on oxidative stress, cGAS/STING and HMGB1/RAGE/TLR2/MYD88 inflammatory axes

    by Diana M.F. Hanna, John Youshia, Sarah Farid Fahmy, Mina Y. George

    Oxaliplatininduces chemobrain in cancer patients/survivors. Nutraceuticalnaringin has antioxidant and anti-inflammatory properties with low oralbioavailability. Our aim was to formulate naringin in chitosan nanoparticles fornose to brain delivery and assess its neuroprotective effect against oxaliplatin-inducedchemobrain in rats. Naringinchitosan nanoparticles were prepared by ionic gelation. Rats were administeredoral naringin (80 mg/kg), intranasal naringin (0.3 mg/kg) or intranasal naringin-loadedchitosan nanoparticles (0.3 mg/kg). Naringin's neuroprotective efficacy wasassessed based on behavioral tests, histopathology, and measuring oxidativestress and inflammatory markers. Selectednanoparticles formulation showed drug loading of 5%, size of 150 nm and werecationic. Intranasal naringin administration enhanced memory function,inhibited hippocampal acetylcholinesterase activity, and corrected oxaliplatin-inducedhistological changes. Moreover, it reduced malondialdehyde and elevated reducedglutathione hippocampal levels. Furthermore, it decreased levels of inflammatorymarkers: NF-kB and TNF-α by 1.25-fold.Upstream to this inflammatory status, intranasal naringin downregulated thehippocampal protein levels of two pathways: cGAS/STINGand HMGB1/RAGE/TLR2/MYD88. Intranasalnaringin-loaded chitosan nanoparticles showed superior amelioration ofoxaliplatin-induced chemobrain in rats at a dose 267-fold lower to thatadministered orally. The potential involvement of cGAS/STINGand HMGB1/RAGE/TLR2/MYD88 pathways in the mechanistic process of eitheroxaliplatin-induced chemobrain or naringin-mediated neuroprotection was evidenced.